Glenzocimab (DB16175): A Comprehensive Review of a Glycoprotein VI Inhibitor for Acute Ischemic Stroke

I. Introduction to Glenzocimab

A. Overview and Rationale for Development

Glenzocimab, also known by its developmental identifier ACT017, is an investigational biopharmaceutical agent that has been primarily developed as an antiplatelet therapy. Its main therapeutic target has been cardiovascular emergencies, with a specific and significant focus on the acute phase of ischemic stroke (AIS).[1] The fundamental rationale for the development of glenzocimab is rooted in the critical unmet need for effective and safe antithrombotic treatments that can be administered rapidly during the hyperacute phase of AIS. The primary goals of such an intervention are to halt the progression of the occlusive thrombus, prevent further thromboembolic events, and improve microcirculatory reperfusion, ideally with a superior safety profile, particularly a diminished risk of bleeding complications when compared with existing antithrombotic or thrombolytic therapies.[1] Glenzocimab was conceived to address the crucial therapeutic window in the initial hours immediately following a stroke, a period where timely and effective intervention is paramount to minimizing irreversible neurological damage.[1]

B. Chemical and Physical Properties